Patents by Inventor Andree Amelsberg

Andree Amelsberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES
    Publication number: 20180360834
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: December 19, 2017
    Publication date: December 20, 2018
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS
    Publication number: 20180086744
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I) wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 29, 2018
    Inventors: Flavio SOLCA, Andree AMELSBERG, Gerd STEHLE, Jacobus C.A. VAN MEEL, Anke BAUM
  • QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES
    Publication number: 20170112835
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 27, 2017
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Quinazoline derivatives for the treatment of cancer diseases
    Patent number: 9539258
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 10, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES
    Publication number: 20150272954
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 1, 2015
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Quinazoline derivatives for the treatment of cancer diseases
    Patent number: 9089571
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: July 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS
    Publication number: 20140199298
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I) wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 17, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Flavio SOLCA, Andree AMELSBERG, Gerd STEHLE, Jacobus C.A. VAN MEEL, Anke BAUM
  • QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES
    Publication number: 20130178487
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: February 14, 2013
    Publication date: July 11, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Quinazoline derivatives for the treatment of cancer diseases
    Patent number: 8404697
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: March 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Gerd Stehle, Jacobus C. A. Van Meel, Anke Baum
  • QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES
    Publication number: 20090306044
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: November 9, 2006
    Publication date: December 10, 2009
    Inventors: Flavio Solca, Andree Amelsberg, Gerd Stehle, Jacobus C.A. Van Meel, Anke Baum
  • COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS
    Publication number: 20090306101
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: November 9, 2006
    Publication date: December 10, 2009
    Inventors: Flavio Solca, Andree Amelsberg, Gerd Stehle, Jacobus C.A. Van Meel, Anke Baum
  • Use of alpha specific antibody BIBH1 in the treatment of cancer
    Publication number: 20030103968
    Abstract: A method of treating a patient suffering from a pathological condition characterized by expression of FAP&agr;, the method comprising administering to the patient a therapeutically effective amount of an antibody which specifically binds to FAP&agr;. A pharmaceutical composition comprising an antibody which specifically binds to FAP&agr;, wherein the antibody is radiolabeled with 131I, 90Y, 186Re, or 188Re, and wherein the antibody has specific activity of from about 0.5 to about 15 mCi/mg, is also provided.
    Type: Application
    Filed: April 11, 2002
    Publication date: June 5, 2003
    Inventors: Andree Amelsberg, Andrew Scott, Paul Tanswell